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Panel Discussion: Mechanisms and Health
Effects of Chromium*
by Charlotte Witmert
The Panel was asked questions that had been pre-
pared prior to the conference as well as queries from
the audience, as follows.
In response to a question from R. Bartlett as to how
Crvl can get past the digestive tract without being re-
duced, M. Costa (New York University Medical Center)
stated that it is, in fact, likely reduced. He emphasized
that the pharmacokinetics of chromium have not been
sufficiently studied.
R. Wedeen (Veterans Administration Medical Cen-
ter, East Orange, NewJersey) was then asked whether
exposure to chromium causes increased renal excretion
of chromium and of other compounds, a finding which
seemed to be alluded to in Mutti's work (1), and ifa) this
is similar to low molecular weight proteinuria and b)
whether the chromium excretion can be correlated with
the air level of chromium. Wedeen replied that he was
quoting in his talk from the work of Mutti's group (1)
that showed both low molecular weight proteinuria and
retinol-binding protein in the urine which is not reab-
sorbed and metabolized. The important point is that
when the urinary chromium levels were greater than
15 ,ug/g urinary creatinine, low molecular weight
proteinuria was observed. Whether the air exposure
was related with the chromium excretion he did not
know. He stated that the problem with the studies of
this group (2) was that they did not really determine
clearance because they did not take into account the
protein binding ofchromium in the serum.
Another question put to Wedeen was whether data
from long-term high-level exposure (4 years) of rats
and dogs to chromium in drinking water (which did not
result in kidney damage) could be extrapolated to hu-
mans. Wedeen replied that the answer is no, especially
if you only look at histological damage to the kidney,
which is a crude approach. He stated that such data
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only support his point that no one has looked properly
for kidney damage, in animals or humans. He added
that the effects in humans must be very subtle, in that
not everyone exposed to chromium gets the same dis-
ease, and these effects are yet to be discerned. His sus-
picion remains high from the information that is avail-
able, and experiments in animals that have failed to
find kidney damage do not convince him to stop looking.
The question was raised as to whether there have
been investigations ofthe effects ofsimultaneous expo-
sure to lead and chromium on DNA synthesis, as this
double exposure is possible for children in a specific
Jersey City school. Such studies have apparently not
been carried out, but Costa voiced the opinion that this
might be an important question as all metals tend to
accumulate in the kidney, and lead causes renal cancer
in rats and causes intranuclear inclusion bodies. Lead
has not been shown to cause cancer in humans, however.
A question was addressed to the entire group as to
what compounds potentiate or act synergistically to in-
crease any toxic or carcinogenic effects of chromium.
M. Sugiyama (Kurume University School of Medicine)
reiterated that vitamin B2 pretreatment of cells in cul-
ture causes dramatic increases of Crv, which increases
the genotoxicity, but the cytotoxicity is not increased;
thus the cytotoxicity and genotoxicity are separate and
perhaps not closely related. Sugiyama then speculated
that the cytotoxicity is the result ofmembrane damage
by chromium. K. Wetterhahn (Dartmouth University)
pointed out that she has also observed that glutathione
(GSH) is actually protective in terms of cytotoxicity
but enhances the genotoxicity of chromium. E. Snow
(New York University Medical Center) responded to a
question about whether her E. coli system had active
SOS repair (an error-prone bacterial repair of DNA
damage) by stating that the cells in which she carried
out mutagenicity studies were wild-type cells which
have an SOS repair system that was not turned on in
advance and that the involvement of SOS repair is be-
ing investigated. She was studying Cr"', and it is not
clear how this relates to the SOS system. She empha-
sized that more work needs to be done with repair
mechanisms.PANEL DISCUSSIONA
A question was raised as to whether it is really cor-
rect that only the Crvy form crosses cell membranes.
Wetterhahn replied that the tetrahedral geometry of
Crl" allows its transport across membranes by anion
carriers. Cr"' does get into cells slowly, certainly liver
and kidney cells, and eventually it reacts with the DNA,
forming different adducts than those formed when Cr"l
is reduced in situ, Costa pointed out that the essential
form of chromium is Cr"', which can chelate fairly sta-
bly to a variety of ligands that can aid its transport.
C. Snyder (New York University Medical Center) reit-
erated that the chromium need not get into the cells to
cause damage, it can just alter some ofthe surface pro-
teins, as his evidence shows. For example, if a kidney
cell is turned into nonself because the (cell surface)
protein is altered next to a major histocompatability
protein, and the kidney cell is recognized as nonself by
helper T-cells, the T-cells will kill the kidney cell.
Costa was questioned as to whether the linkage to
protein (in DNA-protein crosslinks) was the -SH group
and whether the linkage site in DNA is known. He re-
plied that the protein -SH is involved and that the
phosphate ester group and/or the N7 ofguanine appear
to be points of attachment for DNA (based on binding
constants) in these chromium-mediated DNA-protein
crosslinks. He suggested that studies with GSH might
shed some light on binding. Wetterhahn stated that in
studies ofchromium binding to synthetic DNA polymers
she found some degree ofspecificity for chromium bind-
ing to deoxyguanine, although this is not absolute. Ad-
jacent adenines and guanines also lead to high levels of
chromium bound to the DNA. There appears to be a
specificity for purines generally, but the exact site on
the DNA is not known.
In response to a question as to the value ofspeciation
of chromium in biological samples, in view of the rapid
reduction of CrVI, the panel agreed that speciation is
valuable but difficult to carry out, depending on which
oxidation state one is looking at. However, many find-
ings support the premise that Cr"' is the form bound to
DNA.
A question whether chromium is active in cell trans-
formation assays and whether any specific transforma-
tions are correlated with biochemical and genetic find-
ings was answered by Costa by referring to positive
results for lead chromate in Syrian hamster embryo
cell transformation assays and some positive results for
insoluble salts, such as lead chromate, in 1OT1/2 cell
assays. DNA lesions, such as strand breaks and cross-
links, are present in cultured cells, and such lesions cause
these positive results, but specific lesions cannot be yet
connected with specific transformations.
When asked whether the uptake of chromium by mi-
tochondria was studied in intact isolated mitochondria
or in vivo, Wetterhahn replied that chromium is found
in both intact mitochondria and in submitochondrial
particles in in vitro studies and that Crvy is reduced in
mitochondria to Crv by the electron transport chain. She
has not examined mitochondrial DNA for binding of
chromium. She added that researchers have shown that
chromium accumulates in mitochondria ini vivo. She also
responded to a question about similarities between the
extracellular and intracellular reduction of Crvy and
subsequent binding of Cr"' by stating that there are
different compounds that reduce chromate and that the
binding of Cr"' following its production extracellularly
is different from the binding following intracellular
reduction. She reiterated that much of Crvy in blood is
reduced in erythrocytes, although some may be reduced
outside of the erythrocyte and then binds to albumin
and other proteins.
In response to a question as to whether CrVI plays a
role as a tumor promotor, Wetterhahn replied that it
could have such an action by way of its capacity to
cause free radical formation. Since the rat is not a good
animal model for chromium-induced carcinogenesis, and
as inhalation studies have generally been negative, it is
difficult to evaluate the possible tumor promotion activ-
ity of chromium. Costa added that there are many
problems with models for carcinogenesis of chromium,
that inhalation studies with chromium in rats are diffi-
cult as rats are nose-only breathers. Snyder commented
on pellet implant studies conducted at New York Uni-
versity about 20 years ago, which showed that chromium
can act as a lung carcinogen in rats; subsequent aerosol
studies carried out by the same group showed that about
4% ofthe treated rats got lung tumors, a high percent-
age for rats. Whether this was a promotion mechanism
is not known.
Sugiyama was asked whether many effects of CrVI
could be attributed to its nonspecific oxidizing action,
and thus whether all antioxidants might be expected to
protect against the toxicity. His response was that he
could not generalize from his studies that all antioxidants
would be protective. Extracellular interactions might
be important for antioxidants, and he had only studied
increased intracellular vitamin E. Wetterhahn agreed
that the oxidizing activity ofCrvy is not the sole mecha-
nisms ofits toxicity; it is not that nonspecific. The activ-
ity of chromium is under kinetic, not thermodynamic,
control, so there are compounds that chromium would
be expected to oxidize, and yet at physiological pH that
doe not happen within a reasonable time scale. She also
reminded us that we must distinguish genotoxicity from
cytotoxicity citing the samples ofglutathione and vita-
min B1 being activating in genotoxicity studies whereas
ascorbate and vitamin E are not, and yet glutathione is
also considered an antioxidant. She emphasized that one
cannot make generalizations about the oxidizing action
ofchromium and its toxicity.
Wedeen was asked to identify the anatomic end point
of the chromium effect on chronic functional deficiency
in the kidney. His answer was that decreased renal fil-
tration is the definition of renal disease but that it is
difficult to distinguish this effect from that of aging.
Renal failure may be multifactorial.
R. Albert asked whether the mucosol lining of the
respiratory tract reacts quickly enough to reduce Crvy
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to serve as a protective barrier against chromium for
this tract by preventing its absorption. Snydcer replied
that the mucous lining does not go all the way down in
the respiratory tract and that this lining probably does
not serve as a good barrier for small chromate par-
ticles, although the size of the inhaled chromate par-
ticles is not really known. He added that he thought
that there were some human alveolar tumors fiom
chromium. Albert cited the mucosal protective effect
on formaldehyde. Costa commented that the competition
for reduction and absorption is a matter ofconcentration
and solubility of the specific chromate; particles may
produce local effects. Wetterhahn replied that the up-
take into cells is very rapid, and thus, although there
may be some reduction extracellularly, reduction by the
mucosa will not be sufficiently rapid as a competing
reaction to prevent the entry ofCr'' into cells. Snow also
explained that some binding of Cr"' to protein may be
very rapid but not necessarily very tight so that this
relatively loosely bound Cr"ll could still be available for
further toxic reactions. It was the consensus that the
extracellular reduction in the mucosal lining is not so
rapid as to impair the uptake into cells.
The question was raised whether very large doses of
Cr'l are required to bypass the extracellular binding of
Cr'" and whether these are really relate(d to doses to
which the public may be exposedl. The levTels of chro-
mium to which humans are exposed are not known, but
Snyder explained that the doses required for his immu-
nological responses were not high, and humans would
perhaps be exposed to nearly such levels (1 mg/L in the
drinking water). How much is reduced in the stomach
in humans is not known, so the intestinal exposure to
the trivalent versus the hexavalent state is not known.
Another point was made by Costa's group that in his
work of exposure to Cr'" in drinking water, some chro-
mium got into the red blood cells, indicating the presence
of Cr'' in the blood stream as Cr'' and thus not all was
reduced in the gastrointestinal tract. Bartlett queried
whether some ofthe Cr"'ll could get reoxidized in the di-
gestive tract, but Costa did not think this was possible.
Snyder was also asked about the immunological
effects of long-term exposure to chromium. This is not
yet known, but it can be speculated that there may be
resultant autoimmune diseases. It was then suggested
that Jersey City may have an increased incidence of
lupus, but Wedeen replied that this is not true. He also
commented on an immune response to low doses of
mercury which he has presented, which is a T-cell
polyclonal release in the rat, which is a little different
from the mechanism Snyder proposed. Snyder pointed
out that T-cells are accessory cells in the antibody re-
sponse, and therefore they may sometimes respond to
altered cell protein, antigen, not by killing the cell but
by increasing the antibody response. He added that this
is rampant speculation, but things are starting to be
tied together as to why there is kidney damage not
only from chromium but from other metals as well, and
why we are getting enhanced immunological response.
It was also noted by Sugiyama that no lipid per-
oxidation was found by addition of 1 mM chromate to
cells in culture, although addition of Crl" to liver
homogenates causes lipid peroxidation. This indicates
that in cell culture situations the Cr"' is immediately
reduced to Cr" and Cr"' and so does not cause the same
effects as in t'itro. Even though free radicals may be
produced, there is no lipid peroxidation, so that the as-
sociation offree radical formation and lipid peroxidation
riequires additional research.
It was asked whether the use ofmoist soil for experi-
ments would be an improvement over previous expo-
sures, and the answer was that such experiments are
not now planned, as the reversal of the drying effects
takes place in the animal. Snyder suggested that he
may try Cr"' with the same immunological experiments
he is now carrying out with Cr''. The similarity of Cr"'
geometry (with water or DNA as ligands) to cisplatinum
was briefly discussed, but there is no relevant similarity
ofthese compounds and their effects, especially in regard
to the renal toxicity of cisplatinum, as compared with
the Cr"' in the nucleus. Wedeen also emphasized that
the CrIl form of chromium may not be much less toxic
than the Cr'', particularly in the kidney, as tubular cells
have the unique capacity to allow many compounds to
cross membranes that would not be allowed by other
cells. Thus Cr"' may be able to cross renal cells despite
the fact that only Cr'I is transported across other mem-
branes.
When asked about the half-life of reduced chromium,
Costa explained that Cr"' stays in the red cell for the
life ofthe cell and at cell lysis the chromium is released
andl excreted as Cr"'. Weeden commented that his ob-
servations indicate that the tl1 for chromium in humans
appears to be about 30 days; at least the blood levels
and excretion levels drop to about 50% in 30 days.
The study ofthe species of chromium found in vito is
very (lifflcult, it was emphasized, due to changes during
the extraction processes. Costa emphasized that with
Cr"l and with other metals, distribution studies are very
difficult because of ligand exchange reactions. It was
also commented that the results of (listribution studies
for Cr"' are better than those of other metals because
ofthe relative inertness ofCr"'. It is still difficult, how-
ever, and the speciation ofchromium at various locations
in the body is not defilnitely known.
The panel members agreed that the research to deflne
the ultimate toxin/carcinogen of chromium was of the
utmost importance and that this is related to the
speciation and pharmacokinetics of chromium in mam-
malian tissues. It also appears that renal effects of
chromium have not been well studied and in humans
this is also a high priority.
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